We retrospectively investigated the correlation between the expressions of total- and phosphorylated-EGFR and the clinical efficacy of ALK-TKI alectinib in 26 treatment-naïve patients with ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.